Transforming growth factor beta (TGFβ) is a cytokine that is secreted by various cell types, including macrophages, and functions in cell growth, cell differentiation, apoptosis and cellular ...

(“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

The Series C financing was led by Frazier Life Sciences with participation from additional new investors that included Vivo ...

Keros Therapeutics, Inc. has recently announced its participation in two upcoming healthcare conferences. The company's Chair ...

Endothelial cells are also likely to participate in activation, both by production of cellular fibronectin and via conversion of transforming growth factor (TGF)-beta from the latent to active ...

is a clinical-stage biopharmaceutical company that specializes in developing and commercializing novel therapeutics for treating disorders related to dysfunctional signaling of the transforming growth ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has received an average recommendation of “Buy” from the twelve ...

Researchers have developed the most comprehensive atlas linking plasma proteins to diseases and traits in over 53,000 ...

Smart beta ETFs commonly include strategies that are equally weighted, fundamentally weighted, factor-based ... behaviors or metrics like earnings growth, the extent to which the stock moves ...

Emerging markets are showing significant potential right now, thanks to evolving markets, rising demand, and supportive ...